LC
AIMT

Lindbrook Capital’s Aimmune Therapeutics AIMT Stock Holding History

Lindbrook Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-156
Closed -$5K – 1936
2020
Q3 		$5K Hold
156
– – ﹤0.01% 1146
2020
Q2 		$3K Sell
156
-162
-51% -$2.75K ﹤0.01% 1335
2020
Q1 		$5K Hold
318
– – ﹤0.01% 1044
2019
Q4 		$11K Hold
318
– – ﹤0.01% 917
2019
Q3 		$7K Hold
318
– – ﹤0.01% 1013
2019
Q2 		$6K Hold
318
– – ﹤0.01% 1041
2019
Q1 		$7K Hold
318
– – ﹤0.01% 1014
2018
Q4 		$7K Buy
+318
New +$8.23K ﹤0.01% 944

Lindbrook Capital's AIMT Position: Q4 2020 in Review

Lindbrook Capital sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 156 shares — an estimated $5K sold.

Lindbrook Capital first reported a position in AIMT in Q4 2018 and held it in 8 quarters. The position peaked at $11K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Lindbrook Capital reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lindbrook Capital sold 156 Aimmune Therapeutics shares in Q4 2020, an estimated $5K.
  • Lindbrook Capital first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 8 quarters.
  • Lindbrook Capital's Aimmune Therapeutics position peaked at $11K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Lindbrook Capital's 13F filing for Q4 2020, filed 27 Jan 2021.